"Histone Deacetylase 6" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class II histone deacetylase that removes acetyl groups from N-terminal LYSINES of HISTONE H2A; HISTONE H2B; HISTONE H3; and HISTONE H4. It plays a critical role in EPIGENETIC REPRESSION and regulation of GENETIC TRANSCRIPTION, as well as CELL MOTILITY through deacetylation of TUBULIN. It also targets misfolded proteins for clearance by AUTOPHAGY when MOLECULAR CHAPERONE-mediated folding is overwhelmed.
| Descriptor ID |
D000073864
|
| MeSH Number(s) |
D08.811.277.087.520.350
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Histone Deacetylase 6".
Below are MeSH descriptors whose meaning is more specific than "Histone Deacetylase 6".
This graph shows the total number of publications written about "Histone Deacetylase 6" by people in this website by year, and whether "Histone Deacetylase 6" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Histone Deacetylase 6" by people in Profiles.
-
The lysosomal Ragulator complex activates NLRP3 inflammasome in?vivo via HDAC6. EMBO J. 2023 01 04; 42(1):e111389.
-
HDAC6 Inhibition Reverses Cisplatin-Induced Mechanical Hypersensitivity via Tonic Delta Opioid Receptor Signaling. J Neurosci. 2022 10 19; 42(42):7862-7874.
-
HDAC6 inhibition reverses long-term doxorubicin-induced cognitive dysfunction by restoring microglia homeostasis and synaptic integrity. Theranostics. 2022; 12(2):603-619.
-
An HDAC6 inhibitor reverses chemotherapy-induced mechanical hypersensitivity via an IL-10 and macrophage dependent pathway. Brain Behav Immun. 2022 02; 100:287-296.
-
Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors. Clin Cancer Res. 2021 07 01; 27(13):3584-3594.
-
HDAC6 inhibition restores TDP-43 pathology and axonal transport defects in human motor neurons with TARDBP mutations. EMBO J. 2021 04 01; 40(7):e106177.
-
Sperm-borne miR-202 targets SEPT7 and regulates first cleavage of bovine embryos via cytoskeletal remodeling. Development. 2021 03 05; 148(5).
-
HDAC6-dependent ciliophagy is involved in ciliary loss and cholangiocarcinoma growth in human cells and murine models. Am J Physiol Gastrointest Liver Physiol. 2020 06 01; 318(6):G1022-G1033.
-
Cell-specific role of histone deacetylase 6 in chemotherapy-induced mechanical allodynia and loss of intraepidermal nerve fibers. Pain. 2019 12; 160(12):2877-2890.
-
Activity-by-contact model of enhancer-promoter regulation from thousands of CRISPR perturbations. Nat Genet. 2019 Dec; 51(12):1664-1669.